🟢 Outlook Therapeutics is trading 5.5% up in pre-market — cause unclear

Outlook Therapeutics is trading at $0.52, up 5.48% in pre-market, with the move’s cause unclear.

• No fresh company-specific announcement explaining the October 20 pre-market rise was identified; the latest company release located was the October 9 commercial-leadership appointment.
• The October 1 LYTENAVA J-code application is older news, not a clear new catalyst.
• The supplied sector context has biotech down pre-market, so it does not explain the upward move.